Pivya FDA Approval History
FDA Approved: Yes (First approved April 24, 2024)
Brand name: Pivya
Generic name: pivmecillinam
Dosage form: Tablets
Company: Utility Therapeutics Ltd.
Treatment for: Urinary Tract Infection
Pivya (pivmecillinam) is a penicillin class antibacterial for use in the treatment of uncomplicated urinary tract infections.
- Pivya is indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Pivya and other antibacterial drugs, Pivya should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Development timeline for Pivya
| Date | Article |
|---|---|
| Apr 24, 2024 | Approval FDA Approves Pivya (pivmecillinam) for the Treatment of Uncomplicated Urinary Tract Infections |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
